- Home
- MERC vs ELDN Comparison
MERC vs ELDN Comparison
Compare MERC & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MERC | ELDN |
|---|---|---|
| Founded | 1968 | 2004 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Paper | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 106.5M | 123.1M |
| IPO Year | 1987 | N/A |
Fundamental Metrics
Financial Performance| Metric | MERC | ELDN |
|---|---|---|
| Price | $2.07 | $1.60 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | $3.00 | ★ $8.50 |
| AVG Volume (30 Days) | 737.4K | ★ 1.0M |
| Earning Date | 11-06-2025 | 11-14-2025 |
| Dividend Yield | ★ 7.35% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,906,971,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $12.53 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.48 | $1.35 |
| 52 Week High | $8.28 | $4.98 |
Technical Indicators
Market Signals| Indicator | MERC | ELDN |
|---|---|---|
| Relative Strength Index (RSI) | 56.41 | 40.25 |
| Support Level | $1.98 | $1.51 |
| Resistance Level | $2.15 | $1.69 |
| Average True Range (ATR) | 0.12 | 0.10 |
| MACD | 0.03 | 0.05 |
| Stochastic Oscillator | 51.82 | 30.61 |
Price Performance
Historical ComparisonAbout MERC Mercer International Inc.
Mercer International Inc is a forest products company with two reportable operating segments in pulp and solid wood. The pulp segment consists of the manufacture, sale, and distribution of pulp, electricity, and chemicals. The company has a geographical presence in the USA, Germany, China, and Other countries, where the majority of revenue is generated from the USA. The majority of the revenue is generated from the Pulp segment.
About ELDN Eledon Pharmaceuticals Inc.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.